REFERENCES
1. de Kock L, Wu MK, Foulkes WD. Ten years of DICER1 mutations: provenance, distribution, and associated phenotypes. Hum Mutat 2019;40:1939-1953. 2. Stewart DR, Best AF, Williams GM, et al. Neoplasm risk among individuals with a pathogenic germline variant in DICER1. J Clin Oncol 2019;37:668-676. 3. Hill DA, Ivanovich J, Priest JR, et al. DICER1 mutations in familial pleuropulmonary blastoma. Science 2009;325:965. 4. Brenneman M, Field A, Yang J, et al. Temporal order of RNase IIIb and loss-of-function mutations during development determines phenotype in pleuropulmonary blastoma / DICER1 syndrome: a unique variant of the two-hit tumor suppression model. F1000Res 2015;4:214. 5. Seki M, Yoshida K, Shiraishi Y, et al. Biallelic DICER1 mutations in sporadic pleuropulmonary blastoma. Cancer Res 2014;74:2742-2749. 6. Schultz KA, Stewart DR, Kamihara J, et al. DICER1 tumor predisposition. In: Adam MP, Feldman J, Mirzaa GM, et al. (eds.). GeneReviews®. Seattle: University of Washington; 2014. 7. Schultz KAP, Harris A, Messinger Y, et al. Ovarian tumors related to intronic mutations in DICER1: a report from the international ovarian and testicular stromal tumor registry. Fam Cancer 2016;15:105-110. 8. Verrier F, Dubois d’Enghien C, Gauthier-Villars M, et al.Mutiple DICER1-related lesions associated with a germline deep intronic mutation. Pediatr Blood Cancer 2018;65:e27005. 9. Fraire CR, Mallinger PR, Hatton JN, et al. Intronic germline DICER1 variants in patients with Sertoli-Leydig cell tumor. JCO Precis Oncol 2023;7:e2300189. 10. Apellaniz-Ruiz M, Sabbaghian N, Chong AL, et al.Reclassification of two germline DICER1 splicing variants leads to DICER1 syndrome diagnosis. Fam Cancer 2023;22:487-493. 11. de Kock L, Wang YC, Revil T, et al. High-sensitivity sequencing reveals multi-organ somatic mosaicism causing DICER1 syndrome. J Med Genet 2016;53:43-52. 12. Terraf P, Pareja F, Brown DN, et al. Comprehensive assessment of germline pathogenic variant detection in tumor-only sequencing. Ann Oncol 2022;33:426-433. 13. Kommoss FKF, Stichel D, Mora J, et al. Clinicopathologic and molecular analysis of embryonal rhabdomyosarcoma of the genitourinary tract: evidence for a distinct DICER1-associated subgroup. Mod Pathol 2021;34:1558-1569. 14. Cross SF, Arbuckle S, Priest JR, Marshall G, Charles A, Dalla Pozza L. Familial pleuropulmonary blastoma in Australia. Pediatr Blood Cancer 2010;55:1417-1419. 15. Doros L, Yang J, Dehner L, et al. DICER1 mutations in embryonal rhabdomyosarcomas from children with and without familial PPB-tumor predisposition syndrome. Pediatr Blood Cancer 2012;59:558-560. 16. Miyama Y, Makise N, Miyakawa J, Kume H, Fukayama M, Ushiku T.An autopsy case of prostatic rhabdomyosarcoma with DICER1 hotspot mutation. Pathol Int 2021;71:102-108. 17. Eckstein M, Agaimy A, Woenckhaus J, et al. DICER1 mutation-positive giant botryoid fibroepithelial polyp of the urinary bladder mimicking embryonal rhabdomyosarcoma. Hum Pathol 2019;84:1-7. 18. Schultz KAP, Williams GM, Kamihara J, et al. DICER1 and associated conditions: identification of at-risk individuals and recommended surveillance strategies. Clin Cancer Res 2018;24:2251-2261. 19. Bakhuizen JJ, Hanson H, van der Tuin K, et al. Surveillance recommendations for DICER1 pathogenic variant carriers: a report from the SIOPE Host Genome Working Group and CanGene-CanVar Clinical Guideline Working Group. Fam Cancer 2021;20:337-348. 20. Faure A, Atkinson J, Bouty A, et al. DICER1 pleuropulmonary blastoma familial tumour predisposition syndrome: what the paediatric urologist needs to know. J Pediatr Urol 2016;12:5-10.